Lance Yuen, the newly appointed chief of CK Life Sciences International, is leveraging his extensive experience with global pharmaceutical giants to propel the healthcare company forward. With a background at companies like Bristol-Myers Squibb and Bayer, Yuen aims to bring new drug candidates to market and boost the company’s financial prospects.
Describing himself as a “commercialisation expert,” Yuen emphasizes the importance of commercial teams being involved early in the drug development process. He envisions CK Life Sciences making significant strides in cancer treatment through the development of innovative therapies, diagnostics, and prevention methods.
Yuen’s track record includes leading consumer health units and spearheading negotiations for patient access to life-changing medications. Recently, CK Life Sciences announced a merger with Virios Therapeutics, a move that signals the company’s commitment to advancing treatments for conditions like chemotherapy-induced nerve pain and chronic pain disorders.